Physician profile
Vinod Ravi
NPI 1073703401
$93,203.59
in general payments reported to CMS, 2019-2025
6 companies · $34K in 2025
The $34K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2021: $4,595 · 2022: $4,743 · 2023: $11K · 2024: $19K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Honoraria: $12K · Travel and Lodging: $4,381 · Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,248.75 |
| Honoraria | $12,245.00 |
| Travel and Lodging | $4,380.67 |
| Food and Beverage | $2,123.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46,607.90 | 2019-2025 | Turalio, Vanflyta |
| Emd Serono, INC. | $21,730.11 | 2025 | |
| Deciphera Pharmaceuticals INC. | $18,550.61 | 2021-2024 | Vimseltinib, Qinlock |
| Aadi Bioscience, INC. | $4,214.97 | 2022-2024 | Fyarro |
| Bayer Healthcare Pharmaceuticals INC. | $2,100.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.